Eli Lilly wants to study wider use for weight-loss drugs, FT reports

Eli Lilly is planning to study its anti-obesity medications on people who are not overweight but are at risk of weight gain, The Financial Times’ Oliver Barnes reports. CEO Dave Ricks told the publication that the drugmaker is looking to study the medications and that “Maybe the cut-off point of (a BMI of) 27 we use in northern Europe and the US for entry into the studies isn’t appropriate. Maybe we should use (a BMI of) 25. Long term, should we look at health maintenance? Maybe we will.” Ricks says it is possible that drugs like Mounjaro and Zepbound could be rolled out to people with a BMI below 25 who are classified as having a healthy weight but have “a BMI of 24.9 and (are) saying I’d like to not get diabetes in my life…or vascular dementia” or face an increased stroke risk.